Navigation Links
Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
Date:5/11/2009

Tampa, Fla. (May. 11, 2009) Transplanted embryonic stem cells are recognized as a potential treatment for patients suffering from the effects of spinal cord injury (SCI). However, in studies using embryonic stem cells transplanted into SCI laboratory animals, a serious drawback has been the development of tumors following transplantation.

Publishing in the current issue of Cell Transplantation (Vol. 18 No.1), a team of Japanese researchers describe their study that demonstrates a way to eliminate the problem of tumor growth by co-transplanting bone marrow stem cells (BMSCs) along with embryonic stem cells.

"Our study results suggest that co-transplanting BMSCs induce undifferentiated embryonic stem cells to differentiate into a neuronal lineage by neurotrophic factor production, resulting in suppression of tumor formation in SCI model mice," said corresponding author Dr. Masahide Yoshikawa of the Nara Medical University. "The known multipotency of BMSCs during differentiation and their known ability to produce neurotrophic factors, such as nerve growth factor, led us to speculate that co-transplantation of ES cells and BMSCs would provide an advantage over transplantation of ES cells alone."

A control group of mice that only received ES cells developed tumors at the grafted site and their behavioral improvement ceased after three weeks. No tumors developed in the co-transplantation group and behavioral improvement continued over the five-week study.

To date, no effective medical therapy has been available for SCI patients. While ES cells have been thought to represent a potential resource for therapy, the hurdle of tumor formation has impeded efforts. Co-transplantation of BMSCs appears to overcome the tumor hurdle, suggesting to the researchers that their success can provide a path toward human trials.

"The entire mechanism of suppressed tumor development following co-transplantation remains to be elucidated," says Dr. Yoshikawa. "We considered that the BMSCs played an important role in preventing tumors and speculate that one of the mechanisms by which BMSCs promote the differentiation of ES cells is related to secreted soluble factors, including neurotrophic factors."

According to Dr. Yoshikawa, the transplanted BMSCs survived in the grafted site for at least five weeks after transplantation and maintained their ability to produce NGF.

"These findings are extremely important and emphasize the need for additional study on how embryonic stem cells may be used to treat human neurological problems in the not too distant future," commented Section Editor Dr. John Sladek, professor of pediatrics and neuroscience at the University of Colorado School of Medicine.


'/>"/>

Contact: Dr. Masahide Yoshikawa
myoshika@naramed-u.ac.jp
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related medicine news :

1. Bone Marrow Registry to Launch Groundbreaking Fundraising Technology to Overcome Madoff Crisis
2. A new method for bone-marrow-derived liver stem cells isolation and proliferation
3. Blood, Marrow Drive Offers Hope for Baseball Player, 15
4. After heart attack, bone marrow stem cells increase blood flow within heart
5. Why Blood and Bone Marrow Donors Are So Important: Extreme Makeover: Home Edition Profiles Blood Drive Honoree Lizzie Bell
6. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
7. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
8. Study uses bone marrow stem cells to regenerate skin
9. Stem cells and leukemia battle for marrow microenvironment
10. Aflac Agents and Employees Boost Bone Marrow Registry
11. Experimental Drug Fights Bone Marrow Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... Fla. "I used this old family recipe, which is meant to relieve gout and ... it gave me a 12-hour energy boost every time. It relieved what VA doctors ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: